Wells Fargo & Company Sangamo Therapeutics, Inc Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SGMO
# of Institutions
136Shares Held
86.5MCall Options Held
35.9KPut Options Held
156K-
Wasatch Advisors Inc Salt Lake City, UT20.1MShares$35 Million0.04% of portfolio
-
Armistice Capital, LLC New York, NY14.1MShares$24.5 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$20.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$8.18 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA4.56MShares$7.94 Million0.01% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $272M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...